The BRUIN CLL-322 trial evaluated the safety and efficacy of pirtobrutinib plus venetoclax and rituximab in previously treated CLL/SLL patients.

This antibody-drug conjugate targets a specific protein associated with poor prognosis in patients whose disease progressed after platinum-based chemotherapy.

STAT6 degradation is expected to provide a clinical benefit for patients with Type 2 inflammatory diseases, including asthma.

The contaminated products, distributed exclusively to physician offices, may increase the risk for infection, skin irritation, or delayed wound healing.

Despite the initiation of a phase 3 confirmatory trial, the FDA remains unsatisfied with the interpretability of phase 2 data for Replimune’s oncolytic immunotherapy.

HealthDay News — For men with locally advanced prostate cancer, transdermal estradiol (tE2) patches are noninferior to ...

HealthDay News — Influenza vaccination may offer cardiovascular protection even when it does not prevent infection, according to a study published online April 2 in Eurosurveillance.

The report, from the US Centers for Disease Control and Prevention (CDC), found that COVID vaccines reduced emergency room ...

Access to the pill has become a major issue in the wake of the 2022 US Supreme Court decision that allowed states to ban abortion. HealthDay News — US District Judge David Joseph turned down Louisiana ...

HealthDay News — Growing demand for estrogen patches to relieve menopause symptoms has led to shortages, leaving women searching multiple pharmacies or switching medications. Experts say the shortages ...